- Home
- CGEM
as of 12-09-2025 3:46pm EST
$12.37
$0.07
-0.56%
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Chart Type:
Time Range:
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 671.7M | IPO Year: | 2021 |
| Target Price: | $28.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.68 - $13.60 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered CGEM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.84%
75.84%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cullinan Oncology Inc. (CGEM)
Michaelson Jennifer
Sell
Chief Scientific Officer
CGEM Nov 24, 2025
Avg Cost/Share
$12.30
Shares
4,000
Total Value
$49,200.00
Owned After
138,004
SEC Form 4
Lynx1 Capital Management LP
Buy
10% Owner
CGEM Oct 28, 2025
Avg Cost/Share
$8.40
Shares
165,667
Total Value
$1,391,685.63
Owned After
8,963,500
SEC Form 4
Lynx1 Capital Management LP
Buy
10% Owner
CGEM Oct 17, 2025
Avg Cost/Share
$7.84
Shares
32,217
Total Value
$252,565.17
Owned After
8,963,500
SEC Form 4
Lynx1 Capital Management LP
Buy
10% Owner
CGEM Oct 16, 2025
Avg Cost/Share
$8.86
Shares
150,000
Total Value
$1,328,250.00
Owned After
8,963,500
SEC Form 4
Lynx1 Capital Management LP
Buy
10% Owner
CGEM Oct 15, 2025
Avg Cost/Share
$7.94
Shares
51,500
Total Value
$409,049.05
Owned After
8,963,500
SEC Form 4
Lynx1 Capital Management LP
Buy
10% Owner
CGEM Oct 14, 2025
Avg Cost/Share
$7.59
Shares
15,032
Total Value
$114,047.78
Owned After
8,963,500
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Nov 24, 2025 | Sell | $12.30 | 4,000 | $49,200.00 | 138,004 | |
| Lynx1 Capital Management LP | CGEM | 10% Owner | Oct 28, 2025 | Buy | $8.40 | 165,667 | $1,391,685.63 | 8,963,500 | |
| Lynx1 Capital Management LP | CGEM | 10% Owner | Oct 17, 2025 | Buy | $7.84 | 32,217 | $252,565.17 | 8,963,500 | |
| Lynx1 Capital Management LP | CGEM | 10% Owner | Oct 16, 2025 | Buy | $8.86 | 150,000 | $1,328,250.00 | 8,963,500 | |
| Lynx1 Capital Management LP | CGEM | 10% Owner | Oct 15, 2025 | Buy | $7.94 | 51,500 | $409,049.05 | 8,963,500 | |
| Lynx1 Capital Management LP | CGEM | 10% Owner | Oct 14, 2025 | Buy | $7.59 | 15,032 | $114,047.78 | 8,963,500 |
Latest Cullinan Oncology Inc. News
CGEM Breaking Stock News: Dive into CGEM Ticker-Specific Updates for Smart Investing
Compare CGEM vs Leading Stocks
See how CGEM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CGEM Cullinan Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.